- Sections
- C - Chimie; métallurgie
- C07K - Peptides
- C07K 16/08 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
Détention brevets de la classe C07K 16/08
Brevets de cette classe: 1326
Historique des publications depuis 10 ans
|
67
|
80
|
87
|
111
|
101
|
106
|
127
|
116
|
115
|
33
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 3650 |
22 |
| Novartis AG | 11238 |
21 |
| Deutsches Krebsforschungszentrum | 417 |
19 |
| Genentech, Inc. | 3742 |
18 |
| The Regents of the University of California | 18943 |
16 |
| Duke University | 2872 |
16 |
| City of Hope | 943 |
16 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
14 |
| Xiamen University | 488 |
14 |
| Humabs Biomed SA | 115 |
13 |
| Yang Sheng Tang Company Limited | 56 |
13 |
| Institute for Research in Biomedicine | 95 |
12 |
| Pontificia Universidad Catolica de Chile | 268 |
12 |
| VIR Biotechnology, Inc. | 114 |
12 |
| Xencor, Inc. | 403 |
12 |
| The Rockefeller University | 562 |
11 |
| The University of North Carolina at Chapel Hill | 1928 |
11 |
| Vanderbilt University | 1731 |
11 |
| Icahn School of Medicine at Mount Sinai | 859 |
10 |
| F. Hoffmann-La Roche AG | 7958 |
9 |
| Autres propriétaires | 1044 |